West Pharmaceutical Servi... (WST)
West Pharmaceutical Services Statistics
Share Statistics
West Pharmaceutical Services has 72.29M shares outstanding. The number of shares has increased by -1.07% in one year.
Shares Outstanding | 72.29M |
Shares Change (YoY) | -1.07% |
Shares Change (QoQ) | -0.16% |
Owned by Institutions (%) | 95.73% |
Shares Floating | 71.86M |
Failed to Deliver (FTD) Shares | 789 |
FTD / Avg. Volume | 0.08% |
Short Selling Information
The latest short interest is 1.5M, so 2.07% of the outstanding shares have been sold short.
Short Interest | 1.5M |
Short % of Shares Out | 2.07% |
Short % of Float | 2.09% |
Short Ratio (days to cover) | 2.78 |
Valuation Ratios
The PE ratio is 48.53 and the forward PE ratio is 45.66. West Pharmaceutical Services's PEG ratio is -3.13.
PE Ratio | 48.53 |
Forward PE | 45.66 |
PS Ratio | 8.26 |
Forward PS | 4.5 |
PB Ratio | 8.91 |
P/FCF Ratio | 86.51 |
PEG Ratio | -3.13 |
Enterprise Valuation
West Pharmaceutical Services Inc. has an Enterprise Value (EV) of 25.62B.
EV / Earnings | 51.99 |
EV / Sales | 8.85 |
EV / EBITDA | 34.44 |
EV / EBIT | 44.95 |
EV / FCF | 92.68 |
Financial Position
The company has a current ratio of 2.79, with a Debt / Equity ratio of 0.11.
Current Ratio | 2.79 |
Quick Ratio | 2.11 |
Debt / Equity | 0.11 |
Total Debt / Capitalization | 10.13 |
Cash Flow / Debt | 2.16 |
Interest Coverage | 189.97 |
Financial Efficiency
Return on equity (ROE) is 0.18% and return on capital (ROIC) is 15.59%.
Return on Equity (ROE) | 0.18% |
Return on Assets (ROA) | 0.14% |
Return on Capital (ROIC) | 15.59% |
Revenue Per Employee | $272,943.4 |
Profits Per Employee | $46,481.13 |
Employee Count | 10,600 |
Asset Turnover | 0.79 |
Inventory Turnover | 5.03 |
Taxes
Income Tax | 107.5M |
Effective Tax Rate | 0.18 |
Stock Price Statistics
The stock price has increased by -42.9% in the last 52 weeks. The beta is 1.09, so West Pharmaceutical Services's price volatility has been higher than the market average.
Beta | 1.09 |
52-Week Price Change | -42.9% |
50-Day Moving Average | 268.47 |
200-Day Moving Average | 302.22 |
Relative Strength Index (RSI) | 39.77 |
Average Volume (20 Days) | 967.89K |
Income Statement
In the last 12 months, West Pharmaceutical Services had revenue of 2.89B and earned 492.7M in profits. Earnings per share was 6.75.
Revenue | 2.89B |
Gross Profit | 998.5M |
Operating Income | 569.9M |
Net Income | 492.7M |
EBITDA | 743.9M |
EBIT | 569.9M |
Earnings Per Share (EPS) | 6.75 |
Balance Sheet
The company has 484.6M in cash and 302.3M in debt, giving a net cash position of 182.3M.
Cash & Cash Equivalents | 484.6M |
Total Debt | 302.3M |
Net Cash | 182.3M |
Retained Earnings | 3.96B |
Total Assets | 3.64B |
Working Capital | 987.7M |
Cash Flow
In the last 12 months, operating cash flow was 653.4M and capital expenditures -377M, giving a free cash flow of 276.4M.
Operating Cash Flow | 653.4M |
Capital Expenditures | -377M |
Free Cash Flow | 276.4M |
FCF Per Share | 3.79 |
Margins
Gross margin is 34.51%, with operating and profit margins of 19.7% and 17.03%.
Gross Margin | 34.51% |
Operating Margin | 19.7% |
Pretax Margin | 20.24% |
Profit Margin | 17.03% |
EBITDA Margin | 25.71% |
EBIT Margin | 19.7% |
FCF Margin | 9.55% |
Dividends & Yields
WST pays an annual dividend of $0.83, which amounts to a dividend yield of 0.37%.
Dividend Per Share | $0.83 |
Dividend Yield | 0.37% |
Dividend Growth (YoY) | 5% |
Payout Ratio | 12.43% |
Earnings Yield | 2.99% |
FCF Yield | 1.69% |
Analyst Forecast
The average price target for WST is $355, which is 57.1% higher than the current price. The consensus rating is "Buy".
Price Target | $355 |
Price Target Difference | 57.1% |
Analyst Consensus | Buy |
Analyst Count | 6 |
Stock Splits
The last stock split was on Sep 27, 2013. It was a forward split with a ratio of 2:1.
Last Split Date | Sep 27, 2013 |
Split Type | forward |
Split Ratio | 2:1 |
Scores
Altman Z-Score | 13.63 |
Piotroski F-Score | 6 |